CONCORD DRUGS
|
CONCORD DRUGS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 0.34 | 0.47 | 1.06 | 1.82 |
| CEPS(Rs) | 1.77 | 2.03 | 2.80 | 3.84 |
| DPS(Rs) | - | - | - | - |
| Book NAV/Share(Rs) | 34.11 | 33.82 | 33.43 | 32.44 |
| Tax Rate(%) | 51.37 | 24.88 | 21.09 | 29.08 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 9.14 | 9.00 | 8.78 | 9.49 |
| EBIT Margin(%) | 6.01 | 5.56 | 5.67 | 6.66 |
| Pre Tax Margin(%) | 1.53 | 1.40 | 2.40 | 3.81 |
| PAT Margin (%) | 0.74 | 1.05 | 1.89 | 2.70 |
| Cash Profit Margin (%) | 3.91 | 4.51 | 5.01 | 5.70 |
| Performance Ratios | ||||
| ROA(%) | 0.54 | 0.81 | 1.72 | 2.82 |
| ROE(%) | 0.99 | 1.45 | 3.31 | 5.62 |
| ROCE(%) | 5.19 | 4.99 | 6.32 | 8.77 |
| Asset Turnover(x) | 0.73 | 0.77 | 0.91 | 1.04 |
| Sales/Fixed Asset(x) | 1.18 | 1.81 | 2.14 | 1.62 |
| Working Capital/Sales(x) | 3.10 | 2.72 | 2.38 | 3.23 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.85 | 0.55 | 0.47 | 0.62 |
| Receivable days | 106.22 | 115.94 | 135.50 | 141.52 |
| Inventory Days | 194.39 | 174.63 | 131.60 | 108.28 |
| Payable days | 67.34 | 56.60 | 78.03 | 96.87 |
| Valuation Parameters | ||||
| PER(x) | 92.44 | 74.45 | 25.95 | 15.90 |
| PCE(x) | 17.59 | 17.34 | 9.79 | 7.55 |
| Price/Book(x) | 0.91 | 1.04 | 0.82 | 0.89 |
| Yield(%) | - | - | - | - |
| EV/Net Sales(x) | 1.11 | 1.17 | 0.81 | 0.71 |
| EV/Core EBITDA(x) | 12.08 | 12.96 | 9.26 | 7.33 |
| EV/EBIT(x) | 18.43 | 21.03 | 14.36 | 10.62 |
| EV/CE(x) | 0.94 | 1.02 | 0.87 | 0.74 |
| M Cap / Sales | 0.69 | 0.78 | 0.49 | 0.43 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 0.71 | -13.74 | -11.66 | - |
| Core EBITDA Growth(%) | 2.39 | -11.54 | -19.54 | - |
| EBIT Growth(%) | 8.88 | -15.52 | -24.78 | - |
| PAT Growth(%) | -28.83 | -52.06 | -38.19 | - |
| EPS Growth(%) | -28.83 | -55.35 | -41.98 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.56 | 0.52 | 0.54 | 0.58 |
| Current Ratio(x) | 1.56 | 1.79 | 2.01 | 1.77 |
| Quick Ratio(x) | 0.59 | 0.69 | 1.08 | 1.03 |
| Interest Cover(x) | 1.34 | 1.34 | 1.73 | 2.34 |
| Total Debt/Mcap(x) | 0.62 | 0.50 | 0.66 | 0.65 |
Compare Financial Ratios of peers of CONCORD DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD DRUGS | ₹94.2 Cr | 1.4% | -6.3% | 10.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,179.0 Cr | -0.4% | 4.3% | 13.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,095.0 Cr | 0.9% | 8.9% | 8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,530.0 Cr | 0.7% | 13% | 46.5% | Stock Analytics | |
| CIPLA | ₹114,318.0 Cr | -1% | -0% | -3.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,742.1 Cr | -3.3% | -8.4% | -4.3% | Stock Analytics | |
CONCORD DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD DRUGS | 1.4% |
-6.3% |
10.7% |
| SENSEX | -0.6% |
-0.1% |
-6.7% |
You may also like the below Video Courses
